Related Experiment Video

Updated: Jun 16, 2026

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence
04:56

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

Securinine induces p73-dependent apoptosis preferentially in p53-deficient colon cancer cells

Sonia Rana1, Kalpana Gupta, Jose Gomez

  • 1Invenio Therapeutics, Cleveland, Ohio, USA.

FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
|February 6, 2010
PubMed

Insights

Securinine selectively kills colon cancer cells lacking p53, offering a targeted therapy. This compound induces apoptosis in p53-null cells by upregulating p73, a novel pathway for cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Targeted cancer therapies aim to kill cancer cells while sparing normal cells.
  • p53 gene inactivation is common in cancer, making p53-null targeting desirable.
  • Existing chemotherapies often have significant toxicities.

Purpose of the Study:

  • To identify agents that preferentially kill p53-null cancer cells.
  • To investigate the mechanism of selective cancer cell killing.
  • To explore novel therapeutic pathways for p53-deficient cancers.

Main Methods:

  • Utilized isogenic colon cancer cell lines differing only in p53 expression (RKO and HCT116).
  • Treated cells with securinine and assessed apoptosis and cell viability.
  • Investigated the role of p53 family members (p73) and downstream effectors (p21) in the mechanism.

Main Results:

  • Securinine demonstrated preferential killing of p53-null HCT116 cells over p53-expressing cells.
  • Securinine induced apoptosis in 73% of p53-null cells at 30 microM.
  • The mechanism involved p73 induction in p53-deficient cells and p53-mediated p21 upregulation in p53-expressing cells.

Conclusions:

  • Securinine exhibits properties of a desirable chemotherapeutic agent by selectively targeting p53-null cancer cells.
  • The p53-dependent regulation of p73 presents a novel pathway for targeting p53-deficient colon cancers.
  • This study identifies a promising therapeutic strategy and mechanism for selective cancer cell elimination.

More Related Videos

Procedure and Key Optimization Strategies for an Automated Capillary Electrophoretic-based Immunoassay Method09:32

Procedure and Key Optimization Strategies for an Automated Capillary Electrophoretic-based Immunoassay Method

Published on: September 10, 2017

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...